Stay updated with breaking news from Petitioner Ocular. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In Mati Therapeutics, Inc. v. Ocular Therapeutix, Inc., the Federal Circuit issued a Rule 36 opinion affirming the Patent Trial and Appeal Board's ("PTAB's") Final Written Decision ("FWD") holding all challenged claims unpatentable.
In Mati Therapeutics, Inc. v. Ocular Therapeutix, Inc., the Federal Circuit issued a Rule 36 opinion affirming the Patent Trial and Appeal Board’s PTAB’s Final Written Decision FWD holding all challenged claims unpatentable.